Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

nt beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo and BUNAVAIL™ are trademarks owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.  All other trademarks and tradenames are owned by their respective owners.

© BioDelivery Sciences International, Inc.  All rights reserved.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Service™
10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 A new ... it easier for research institutions to learn how Apple’s ... data. , The timing is ideal since Apple made ... Research Kit is an open-source framework for developing medical ... provides a way for researchers to collect secure clinical ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, today ... has been added as a clinical trial site for ... patients with refractory glioblastoma multiforme (GBM), the most common ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... GNVC ) today announced its financial results for the third ... $3.6 million ($0.04 per share) for the three months ended September ... per share) in the comparable quarter of 2008. For the nine ... ($0.15 per share), compared to a net loss of $19.6 million ...
... Conference Call on Thursday, November 5, 2009 at 4:30 ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the ... results for the third quarter and nine months ended ... the third quarter of 2009. , The following consolidated ...
... DIEGO, CA, November 5, 2009 Senomyx, Inc. (Nasdaq: ... technologies to discover novel flavor ingredients for the food, beverage, ... reported financial results for the third quarter ended September 30, ... of 2009, compared to $4.0 million for the third quarter ...
Cached Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Earth,s history has been going on for hundreds of millions of ... existed, scientists reported today in the journal Nature . ... organism in the oceans, survives where most other cells would die ... had been theorized that SAR11 was so small and widespread that ...
... University of Alberta study shows that busy beavers are helping Canada ... begin spring nesting. Ponds in Alberta where beavers were active ... geese a better chance at reproductive success, according to the study, ... the first to link beavers to early season nesting habits of ...
... the NSERC Canadian Network for Aquatic Ecosystems (CNAES) will ... made when it comes to this country,s wetlands, lakes ... from the Natural Sciences and Engineering Research Council, in ... organizations, was recently announced as part of the government,s ...
Cached Biology News:A war without end -- with Earth's carbon cycle held in the balance 2Canada's aquatic ecosystems research gets boost from NSERC 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
...
Biology Products: